Data of clinical trials using ex vivo Hsp70 peptide and IL-2 stimulated, autologous NK cells to treat patients with advanced colon and lung cancers after radiochemotherapy (Krause et al., 2004; Multhoff et al., 2020) reveal that the cytolytic activity of patient-derived, anergic NK cells could be re-stimulated by Hsp70 peptide and IL-2, but not by IL-2 alone (Krause et al., 2004). The gene discussed is IL2; the disease is lung carcinoma.